Essential Oils and Plant-Derived Volatile Compounds in the Treatment of Oral Candidiasis: A Systematic Review of Randomized Controlled Trials in Denture Stomatitis
4 affiliations
- 1Department of Periodontal Diseases and Oral Mucosa Diseases, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 40-055 Katowice, Poland
- 2Department of Microbiology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 41-200 Sosnowiec, Poland
- 3Department of Pediatric Dentistry and Preclinical Dentistry, Wrocław Medical University, Krakowska 26, 50-425 Wrocław, Poland
- 4Department of Experimental Dentistry, Wrocław Medical University, Krakowska 26, 50-425 Wrocław, Poland
Abstract
Background: Denture stomatitis, the most common form of oral candidiasis among denture wearers, remains highly prevalent, and antifungal resistance is an emerging concern. Essential oils and plant-derived volatile compounds show broad-spectrum antifungal activity in vitro, generating interest as complementary therapies. This review evaluated the clinical efficacy, mycological efficacy, and safety of these compounds versus conventional antifungals or placebo, based solely on randomized controlled trials (RCTs). Methods: Following PRISMA 2020 guidelines and PROSPERO registration (CRD420261473618), PubMed, Embase, Scopus, and Cochrane CENTRAL were searched on 20 July 2026 for English-language RCTs published up to 30 June 2026 and evaluating topical essential oils or volatile compounds against a conventional antifungal or placebo comparator in oral candidiasis. Two reviewers independently conducted screening, extraction and RoB 2 risk-of-bias assessment. Due to heterogeneity, findings were synthesized narratively. Results: Eight RCTs (347 participants), all in denture stomatitis patients, met inclusion criteria, evaluating oils from Zataria multiflora, Cinnamomum zeylanicum, Melaleuca alternifolia, Pelargonium graveolens, Satureja hortensis, Artemisia sieberi, and clove/cinnamon extracts. In active-comparator trials, no statistically significant differences in clinical outcomes were detected, but these trials were small and underpowered and none defined a non-inferiority margin; mycological efficacy varied, sometimes favoring nystatin or miconazole. Both placebo-controlled trials favored essential oil gels for clinical and mycological recovery. Adverse effects were inconsistently and mostly non-systematically reported; one trial reported vertigo, nausea and vomiting in the essential-oil group. Overall risk of bias was low in three trials and raised some concerns in five for both outcomes. Conclusions: The evidence for essential oils in denture stomatitis is preliminary and insufficient to support replacing conventional antifungal therapy; the findings cannot be extrapolated to other forms of oral candidiasis. Safety data are insufficient to draw firm conclusions. Standardized formulations and larger, well-designed RCTs with longer follow-up and safety assessment are needed.
Related
- IncobotulinumtoxinA for Upper Limb Essential Tremor: A Randomized, Double-Blind, Placebo-Controlled Trial.
- Adjunctive Acorus tatarinowii essential-oil ear-canal packing for idiopathic sudden sensorineural hearing loss: study protocol for a single-center, randomized, double-blind, placebo-controlled clinical trial
- Tocilizumab in Acute Coronary Syndromes: A Systematic Review of Randomized Controlled Trials
- Topical herbal medicine as treatment for chemotherapy-induced peripheral neuropathy: a systematic review of randomized controlled trials
- Perioperative intravenous lidocaine for the prevention of chronic postsurgical pain: a systematic review and meta-analysis of randomized controlled trials
BibTeX
@article{lipka2026essential,
title = {{Essential Oils and Plant-Derived Volatile Compounds in the Treatment of Oral Candidiasis: A Systematic Review of Randomized Controlled Trials in Denture Stomatitis}},
author = {Barbara Lipka and Małgorzata Kępa and Maciej Łopaciński and Aleksandra Warakomska and Maciej Dobrzyński and Marek Ziętek and Dariusz Skaba and Rafał Wiench},
journal = {Journal of Clinical Medicine},
year = {2026},
month = nov,
doi = {10.3390/jcm15218617},
url = {https://www.mdpi.com/2077-0383/15/21/8617},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Essential Oils and Plant-Derived Volatile Compounds in the Treatment of Oral Candidiasis: A Systematic Review of Randomized Controlled Trials in Denture Stomatitis
AU - Barbara Lipka
AU - Małgorzata Kępa
AU - Maciej Łopaciński
AU - Aleksandra Warakomska
AU - Maciej Dobrzyński
AU - Marek Ziętek
AU - Dariusz Skaba
AU - Rafał Wiench
PY - 2026
DA - 2026/11/05
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15218617
UR - https://www.mdpi.com/2077-0383/15/21/8617
AB - Background: Denture stomatitis, the most common form of oral candidiasis among denture wearers, remains highly prevalent, and antifungal resistance is an emerging concern. Essential oils and plant-derived volatile compounds show broad-spectrum antifungal activity in vitro, generating interest as complementary therapies. This review evaluated the clinical efficacy, mycological efficacy, and safety of these compounds versus conventional antifungals or placebo, based solely on randomized controlled trials (RCTs). Methods: Following PRISMA 2020 guidelines and PROSPERO registration (CRD420261473618), PubMed, Embase, Scopus, and Cochrane CENTRAL were searched on 20 July 2026 for English-language RCTs published up to 30 June 2026 and evaluating topical essential oils or volatile compounds against a conventional antifungal or placebo comparator in oral candidiasis. Two reviewers independently conducted screening, extraction and RoB 2 risk-of-bias assessment. Due to heterogeneity, findings were synthesized narratively. Results: Eight RCTs (347 participants), all in denture stomatitis patients, met inclusion criteria, evaluating oils from Zataria multiflora, Cinnamomum zeylanicum, Melaleuca alternifolia, Pelargonium graveolens, Satureja hortensis, Artemisia sieberi, and clove/cinnamon extracts. In active-comparator trials, no statistically significant differences in clinical outcomes were detected, but these trials were small and underpowered and none defined a non-inferiority margin; mycological efficacy varied, sometimes favoring nystatin or miconazole. Both placebo-controlled trials favored essential oil gels for clinical and mycological recovery. Adverse effects were inconsistently and mostly non-systematically reported; one trial reported vertigo, nausea and vomiting in the essential-oil group. Overall risk of bias was low in three trials and raised some concerns in five for both outcomes. Conclusions: The evidence for essential oils in denture stomatitis is preliminary and insufficient to support replacing conventional antifungal therapy; the findings cannot be extrapolated to other forms of oral candidiasis. Safety data are insufficient to draw firm conclusions. Standardized formulations and larger, well-designed RCTs with longer follow-up and safety assessment are needed.
SN - 2077-0383
ER -